MYUNGMOON PHARM CO.,LTD: Operating Profit Turns Positive in Q1 2026, but Net Loss Persists and Litigation Risk Remains
Consolidated revenue: 47,999 million KRW (+4.6% YoY); operating profit 294 million KRW (turned positive); net loss 1,036 million KRW (narrowed loss)
Separate revenue: 45,532 million KRW; operating profit 1,221 million KRW; net loss 803 million KRW (improved from -1,932 million KRW in Q1 2025)
Total borrowings: 173,676 million KRW (consolidated short-term and long-term); quarterly interest expense 1,250 million KRW
Litigation related to choline alfoscerate clinical reassessment: one final loss (950 million KRW); one ongoing appeal for contract invalidation (1,300 million KRW)
R&D expenditure 1,070 million KRW (2.29% of revenue); new product approvals obtained (MMP-326, etc.)
Property, plant and equipment 166,716 million KRW; increase in construction in progress (8,870 million KRW)